- Home
- SLNO vs VRNS Comparison
SLNO vs VRNS Comparison
Compare SLNO & VRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLNO | VRNS |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.5B |
| IPO Year | 2014 | 2013 |
Fundamental Metrics
Financial Performance| Metric | SLNO | VRNS |
|---|---|---|
| Price | $52.77 | $23.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 21 |
| Target Price | ★ $90.13 | $43.80 |
| AVG Volume (30 Days) | ★ 6.0M | 2.0M |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 108.90 | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | $1,450,788.00 | ★ $270,288,000.00 |
| Revenue This Year | $150.46 | $18.87 |
| Revenue Next Year | $50.37 | $17.77 |
| P/E Ratio | $134.78 | ★ N/A |
| Revenue Growth | ★ 138.82 | 24.35 |
| 52 Week Low | $29.43 | $19.70 |
| 52 Week High | $89.12 | $63.90 |
Technical Indicators
Market Signals| Indicator | SLNO | VRNS |
|---|---|---|
| Relative Strength Index (RSI) | 77.61 | 55.23 |
| Support Level | $48.91 | $20.21 |
| Resistance Level | $55.47 | $24.10 |
| Average True Range (ATR) | 1.08 | 1.29 |
| MACD | 1.15 | 0.33 |
| Stochastic Oscillator | 99.91 | 85.30 |
Price Performance
Historical ComparisonAbout SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
About VRNS Varonis Systems Inc.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.